Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (DE:BSX)
XETRA:BSX
BSX Stock Chart & Stats
€87.80
€5.00(5.65%)
At close: 4:00 PM EST
€87.80
€5.00(5.65%)
Day’s Range― - ―
52-Week Range€75.20 - €104.00
Previous CloseN/A
Volume1.38K
Average Volume (3M)7.33K
Market Cap
$128.86B
Enterprise ValueN/A
Total Cash (Recent Filing)$534.00M
Total Debt (Recent Filing)$12.03B
Price to Earnings (P/E)52.0
Beta0.49
Next Earnings
Feb 04, 2026EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding1,481,751,600
10 Day Avg. Volume899
30 Day Avg. Volume7,327
Financial Highlights & Ratios
PEG Ratio4.27
Price to Book (P/B)6.04
Price to Sales (P/S)7.85
P/FCF Ratio49.69
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$108.76Price Target Upside23.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of Nalu Medical is seen as a strong move by BSX, as Nalu's technology is commercially successful and backed by robust clinical data.
Earnings And Revenue GrowthBSX is putting up 2025 revenue growth of 15.5% and EPS growth of 20.5%-21.3% and has one of the best outlooks in medtech for continued strong double digit revenue growth and mid-teens (or higher) EPS growth.
Product PerformanceThe biggest surprise in 3Q25 was the acceleration in WATCHMAN growth to 35% in 3Q25 from 28% in 2Q25 as concomitant use continues to increase.
Bears Say
Future Earnings ImpactThe transaction is expected to be immaterial to BSX's adjusted EPS in 2026, meaning it might not significantly impact earnings initially.
Operational ChallengesEMEA impacted by TAVR valve exit and mid-quarter ERP implementation backlog causing $30M backorder.
Organic Growth SlowdownOrganic growth slowed somewhat to 15.3% in 3Q25 from 17.4% in 2Q25 as BSX lapped the FARAPULSE launch.
Boston Scientific News
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was €75.20 and its highest was €104.00 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $128.86B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Feb 04, 2026 which is in 100 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Oct 22, 2025. The company reported €0.644 earnings per share for the quarter, beating the consensus estimate of €0.613 by €0.031.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.67.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,481,751,600 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of €0.644 in its last earnings report, beating expectations of €0.613. Following the earnings report the stock price went up 4.884%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in DE:BSX
Boston Scientific Stock Smart Score
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Company Deck
BSX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook with significant sales and EPS growth, driven by the success of key products like WATCHMAN and EP. However, there were challenges in the EMEA region and some product lines, particularly due to operational disruptions and market-specific headwinds.View all DE:BSX earnings summariesBSX Revenue Breakdown
64.22% Cardiovascular
35.79% MedSurg
BSX Stock 12 Month Forecast
Average Price Target
€108.76
▲(23.87% Upside)
Technical Analysis
Options Prices
Currently, No data available
---